Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Clinical and biological features of paediatric acute myeloid leukaemia (AML) with primary induction failure in the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 study.

Miyamura T, Moritake H, Nakayama H, Tanaka S, Tomizawa D, Shiba N, Saito AM, Tawa A, Shimada A, Iwamoto S, Hayashi Y, Koike T, Horibe K, Manabe A, Mizutani S, Taga T, Adachi S.

Br J Haematol. 2019 Apr;185(2):284-288. doi: 10.1111/bjh.15799. Epub 2019 Feb 19.

PMID:
30784060
2.

A Simplified Gas Chromatographic Fatty-Acid Analysis by the Direct Saponification/Methylation Procedure and Its Application on Wild Tuna Larvae.

Matsumoto Y, Ando Y, Hiraoka Y, Tawa A, Ohshimo S.

Lipids. 2018 Sep;53(9):919-929. doi: 10.1002/lipd.12098. Epub 2018 Nov 9.

PMID:
30411800
3.

Recurrent CCND3 mutations in MLL-rearranged acute myeloid leukemia.

Matsuo H, Yoshida K, Fukumura K, Nakatani K, Noguchi Y, Takasaki S, Noura M, Shiozawa Y, Shiraishi Y, Chiba K, Tanaka H, Okada A, Nannya Y, Takeda J, Ueno H, Shiba N, Yamato G, Handa H, Ono Y, Hiramoto N, Ishikawa T, Usuki K, Ishiyama K, Miyawaki S, Itonaga H, Miyazaki Y, Kawamura M, Yamaguchi H, Kiyokawa N, Tomizawa D, Taga T, Tawa A, Hayashi Y, Mano H, Miyano S, Kamikubo Y, Ogawa S, Adachi S.

Blood Adv. 2018 Nov 13;2(21):2879-2889. doi: 10.1182/bloodadvances.2018019398.

4.
5.

Risk-stratified therapy for children with FLT3-ITD-positive acute myeloid leukemia: results from the JPLSG AML-05 study.

Shimada A, Iijima-Yamashita Y, Tawa A, Tomizawa D, Yamada M, Norio S, Watanabe T, Taga T, Iwamoto S, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Goto H, Kosaka Y, Saito AM, Kiyokawa N, Horibe K, Hara Y, Oki K, Hayashi Y, Tanaka S, Adachi S.

Int J Hematol. 2018 May;107(5):586-595. doi: 10.1007/s12185-017-2395-x. Epub 2018 Jan 12.

PMID:
29330746
6.

Multiplex fusion gene testing in pediatric acute myeloid leukemia.

Iijima-Yamashita Y, Matsuo H, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Takahashi H, Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K.

Pediatr Int. 2018 Jan;60(1):47-51. doi: 10.1111/ped.13451.

PMID:
29105243
7.

Monitoring of fusion gene transcripts to predict relapse in pediatric acute myeloid leukemia.

Matsuo H, Iijima-Yamashita Y, Yamada M, Deguchi T, Kiyokawa N, Shimada A, Tawa A, Tomizawa D, Taga T, Kinoshita A, Adachi S, Horibe K.

Pediatr Int. 2018 Jan;60(1):41-46. doi: 10.1111/ped.13440.

PMID:
29067751
8.

Prognostic value of genetic mutations in adolescent and young adults with acute myeloid leukemia.

Kuwatsuka Y, Tomizawa D, Kihara R, Nagata Y, Shiba N, Iijima-Yamashita Y, Shimada A, Deguchi T, Miyachi H, Tawa A, Taga T, Kinoshita A, Nakayama H, Kiyokawa N, Saito AM, Koh K, Goto H, Kosaka Y, Asou N, Ohtake S, Miyawaki S, Miyazaki Y, Sakura T, Ozawa Y, Usui N, Kanamori H, Ito Y, Imai K, Suehiro Y, Kobayashi S, Kitamura K, Sakaida E, Ogawa S, Naoe T, Hayashi Y, Horibe K, Manabe A, Mizutani S, Adachi S, Kiyoi H.

Int J Hematol. 2018 Feb;107(2):201-210. doi: 10.1007/s12185-017-2340-z. Epub 2017 Oct 12.

PMID:
29027108
9.

Integrating Concepts in Biology Textbook Increases Learning: Assessment Triangulation Using Concept Inventory, Card Sorting, and MCAT Instruments, Followed by Longitudinal Tracking.

Luckie DB, Hoskinson AM, Griffin CE, Hess AL, Price KJ, Tawa A, Thacker SM.

CBE Life Sci Educ. 2017 Summer;16(2). pii: ar20. doi: 10.1187/cbe.16-06-0204.

10.

Impact of Low-Dose Hydrocortisone on the Incidence of Atrial Fibrillation in Patients With Septic Shock.

Launey Y, Lasocki S, Asehnoune K, Gaudriot B, Chassier C, Cinotti R, Maguet PL, Laksiri L, Mimoz O, Tawa A, Nesseler N, Malledant Y, Perrot B, Seguin P.

J Intensive Care Med. 2017 Jan 1:885066617696847. doi: 10.1177/0885066617696847. [Epub ahead of print]

PMID:
28292220
11.

Risk factors for mortality in postoperative peritonitis in critically ill patients.

Launey Y, Duteurtre B, Larmet R, Nesseler N, Tawa A, Mallédant Y, Seguin P.

World J Crit Care Med. 2017 Feb 4;6(1):48-55. doi: 10.5492/wjccm.v6.i1.48. eCollection 2017 Feb 4.

12.

Long-term Results of the Risk-adapted Treatment for Childhood B-Cell Acute Lymphoblastic Leukemia: Report From the Japan Association of Childhood Leukemia Study ALL-97 Trial.

Horibe K, Yumura-Yagi K, Kudoh T, Nishimura S, Oda M, Yoshida M, Komada Y, Hara J, Tawa A, Usami I, Tanizawa A, Kato K, Kobayashi R, Matsuo K, Hori H; Japan Association of Childhood Leukemia Study (JACLS), Japan.

J Pediatr Hematol Oncol. 2017 Mar;39(2):81-89. doi: 10.1097/MPH.0000000000000760.

PMID:
28169879
13.

ASXL2 mutations are frequently found in pediatric AML patients with t(8;21)/ RUNX1-RUNX1T1 and associated with a better prognosis.

Yamato G, Shiba N, Yoshida K, Shiraishi Y, Hara Y, Ohki K, Okubo J, Okuno H, Chiba K, Tanaka H, Kinoshita A, Moritake H, Kiyokawa N, Tomizawa D, Park MJ, Sotomatsu M, Taga T, Adachi S, Tawa A, Horibe K, Arakawa H, Miyano S, Ogawa S, Hayashi Y.

Genes Chromosomes Cancer. 2017 May;56(5):382-393. doi: 10.1002/gcc.22443. Epub 2017 Feb 14.

PMID:
28063196
14.

Prognostic impact of specific molecular profiles in pediatric acute megakaryoblastic leukemia in non-Down syndrome.

Hara Y, Shiba N, Ohki K, Tabuchi K, Yamato G, Park MJ, Tomizawa D, Kinoshita A, Shimada A, Arakawa H, Saito AM, Kiyokawa N, Tawa A, Horibe K, Taga T, Adachi S, Taki T, Hayashi Y.

Genes Chromosomes Cancer. 2017 May;56(5):394-404. doi: 10.1002/gcc.22444. Epub 2017 Feb 14.

PMID:
28063190
15.

Acute and late toxicities of pirarubicin in the treatment of childhood acute lymphoblastic leukemia: results from a clinical trial by the Japan Association of Childhood Leukemia Study.

Hori H, Kudoh T, Nishimura S, Oda M, Yoshida M, Hara J, Tawa A, Usami I, Tanizawa A, Yumura-Yagi K, Kato K, Kobayashi R, Komada Y, Matsuo K, Horibe K; Japan Association of Childhood Leukemia Study.

Int J Clin Oncol. 2017 Apr;22(2):387-396. doi: 10.1007/s10147-016-1062-1. Epub 2016 Nov 17.

PMID:
27858183
16.

Whole-exome sequencing reveals the spectrum of gene mutations and the clonal evolution patterns in paediatric acute myeloid leukaemia.

Shiba N, Yoshida K, Shiraishi Y, Okuno Y, Yamato G, Hara Y, Nagata Y, Chiba K, Tanaka H, Terui K, Kato M, Park MJ, Ohki K, Shimada A, Takita J, Tomizawa D, Kudo K, Arakawa H, Adachi S, Taga T, Tawa A, Ito E, Horibe K, Sanada M, Miyano S, Ogawa S, Hayashi Y.

Br J Haematol. 2016 Nov;175(3):476-489. doi: 10.1111/bjh.14247. Epub 2016 Jul 29.

PMID:
27470916
17.

A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.

Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H.

Haemophilia. 2017 Jan;23(1):59-66. doi: 10.1111/hae.13050. Epub 2016 Aug 1.

PMID:
27480904
18.

CXCR4 Overexpression is a Poor Prognostic Factor in Pediatric Acute Myeloid Leukemia With Low Risk: A Report From the Japanese Pediatric Leukemia/Lymphoma Study Group.

Matsuo H, Nakamura N, Tomizawa D, Saito AM, Kiyokawa N, Horibe K, Nishinaka-Arai Y, Tokumasu M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S.

Pediatr Blood Cancer. 2016 Aug;63(8):1394-9. doi: 10.1002/pbc.26035. Epub 2016 May 2.

PMID:
27135782
19.

Severe Sepsis Associated with Lemierre's Syndrome: A Rare but Life-Threatening Disease.

Tawa A, Larmet R, Malledant Y, Seguin P.

Case Rep Crit Care. 2016;2016:1264283. doi: 10.1155/2016/1264283. Epub 2016 Apr 5.

20.

High event-free survival rate with minimum-dose-anthracycline treatment in childhood acute promyelocytic leukaemia: a nationwide prospective study by the Japanese Paediatric Leukaemia/Lymphoma Study Group.

Takahashi H, Watanabe T, Kinoshita A, Yuza Y, Moritake H, Terui K, Iwamoto S, Nakayama H, Shimada A, Kudo K, Taki T, Yabe M, Matsushita H, Yamashita Y, Koike K, Ogawa A, Kosaka Y, Tomizawa D, Taga T, Saito AM, Horibe K, Nakahata T, Miyachi H, Tawa A, Adachi S.

Br J Haematol. 2016 Aug;174(3):437-43. doi: 10.1111/bjh.14068. Epub 2016 Mar 31.

PMID:
27029412
21.

Residual disease detected by multidimensional flow cytometry shows prognostic significance in childhood acute myeloid leukemia with intermediate cytogenetics and negative FLT3-ITD: a report from the Tokyo Children's Cancer Study Group.

Keino D, Kinoshita A, Tomizawa D, Takahashi H, Ida K, Kurosawa H, Koike K, Ota S, Iwasaki N, Fujimura J, Yuza Y, Kiyotani C, Yamamoto S, Osumi T, Ueda T, Mochizuki S, Isoyama K, Hanada R, Tawa A, Manabe A, Toguchi Y, Ohara A.

Int J Hematol. 2016 Apr;103(4):416-22. doi: 10.1007/s12185-016-1937-y. Epub 2016 Jan 18.

PMID:
26781613
22.

High PRDM16 expression identifies a prognostic subgroup of pediatric acute myeloid leukaemia correlated to FLT3-ITD, KMT2A-PTD, and NUP98-NSD1: the results of the Japanese Paediatric Leukaemia/Lymphoma Study Group AML-05 trial.

Shiba N, Ohki K, Kobayashi T, Hara Y, Yamato G, Tanoshima R, Ichikawa H, Tomizawa D, Park MJ, Shimada A, Sotomatsu M, Arakawa H, Horibe K, Adachi S, Taga T, Tawa A, Hayashi Y.

Br J Haematol. 2016 Feb;172(4):581-91. doi: 10.1111/bjh.13869. Epub 2015 Dec 18.

PMID:
26684393
23.

Clinical Impact of Additional Cytogenetic Aberrations, cKIT and RAS Mutations, and Treatment Elements in Pediatric t(8;21)-AML: Results From an International Retrospective Study by the International Berlin-Frankfurt-Münster Study Group.

Klein K, Kaspers G, Harrison CJ, Beverloo HB, Reedijk A, Bongers M, Cloos J, Pession A, Reinhardt D, Zimmerman M, Creutzig U, Dworzak M, Alonzo T, Johnston D, Hirsch B, Zapotocky M, De Moerloose B, Fynn A, Lee V, Taga T, Tawa A, Auvrignon A, Zeller B, Forestier E, Salgado C, Balwierz W, Popa A, Rubnitz J, Raimondi S, Gibson B.

J Clin Oncol. 2015 Dec 20;33(36):4247-58. doi: 10.1200/JCO.2015.61.1947. Epub 2015 Nov 16.

24.

Respiratory syncytial virus infection in infants with acute leukemia: a retrospective survey of the Japanese Pediatric Leukemia/Lymphoma Study Group.

Hatanaka M, Miyamura T, Koh K, Taga T, Tawa A, Hasegawa D, Kajihara R, Adachi S, Ishii E, Tomizawa D.

Int J Hematol. 2015 Dec;102(6):697-701. doi: 10.1007/s12185-015-1890-1. Epub 2015 Oct 31.

PMID:
26520649
25.

Preserved High Probability of Overall Survival with Significant Reduction of Chemotherapy for Myeloid Leukemia in Down Syndrome: A Nationwide Prospective Study in Japan.

Taga T, Watanabe T, Tomizawa D, Kudo K, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Shimada A, Taki T, Toki T, Ito E, Goto H, Koh K, Saito AM, Horibe K, Nakahata T, Tawa A, Adachi S.

Pediatr Blood Cancer. 2016 Feb;63(2):248-54. doi: 10.1002/pbc.25789. Epub 2015 Oct 20.

PMID:
26481183
26.

Outcome of adolescent patients with acute myeloid leukemia treated with pediatric protocols.

Tomizawa D, Watanabe T, Hanada R, Horibe K, Horikoshi Y, Iwamoto S, Kinoshita A, Moritake H, Nakayama H, Shimada A, Taga T, Takahashi H, Tawa A, Terui K, Hori H, Kawano Y, Kikuta A, Manabe A, Adachi S.

Int J Hematol. 2015 Sep;102(3):318-26. doi: 10.1007/s12185-015-1825-x. Epub 2015 Jul 1.

PMID:
26126642
27.

Adverse prognostic impact of KIT mutations in childhood CBF-AML: the results of the Japanese Pediatric Leukemia/Lymphoma Study Group AML-05 trial.

Tokumasu M, Murata C, Shimada A, Ohki K, Hayashi Y, Saito AM, Fujimoto J, Horibe K, Nagao M, Itoh H, Kamikubo Y, Nakayama H, Kinoshita A, Tomizawa D, Taga T, Tawa A, Tanaka S, Heike T, Adachi S.

Leukemia. 2015 Dec;29(12):2438-41. doi: 10.1038/leu.2015.121. Epub 2015 May 15. No abstract available.

PMID:
25975190
28.

CSF3R and CALR mutations in paediatric myeloid disorders and the association of CSF3R mutations with translocations, including t(8; 21).

Sano H, Ohki K, Park MJ, Shiba N, Hara Y, Sotomatsu M, Tomizawa D, Taga T, Kiyokawa N, Tawa A, Horibe K, Adachi S, Hayashi Y.

Br J Haematol. 2015 Aug;170(3):391-7. doi: 10.1111/bjh.13439. Epub 2015 Apr 9.

PMID:
25858548
29.

High expression of EVI1 and MEL1 is a compelling poor prognostic marker of pediatric AML.

Jo A, Mitani S, Shiba N, Hayashi Y, Hara Y, Takahashi H, Tsukimoto I, Tawa A, Horibe K, Tomizawa D, Taga T, Adachi S, Yoshida T, Ichikawa H.

Leukemia. 2015 May;29(5):1076-83. doi: 10.1038/leu.2015.5. Epub 2015 Jan 8.

PMID:
25567132
30.

Acute myeloid leukaemia with myelodysplastic features in children: a report of Japanese Paediatric Leukaemia/Lymphoma Study Group.

Kinoshita A, Miyachi H, Matsushita H, Yabe M, Taki T, Watanabe T, Saito AM, Tomizawa D, Taga T, Takahashi H, Matsuo H, Kodama K, Ohki K, Hayashi Y, Tawa A, Horibe K, Adachi S.

Br J Haematol. 2014 Oct;167(1):80-6. doi: 10.1111/bjh.12993. Epub 2014 Jul 8.

PMID:
25039450
31.

EVI1 overexpression is a poor prognostic factor in pediatric patients with mixed lineage leukemia-AF9 rearranged acute myeloid leukemia.

Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Shiba N, Ohki K, Hayashi Y, Yamashita Y, Shimada A, Tanaka S, Adachi S.

Haematologica. 2014 Nov;99(11):e225-7. doi: 10.3324/haematol.2014.107128. Epub 2014 Jul 11. No abstract available.

32.

Prognostic implications of CEBPA mutations in pediatric acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Matsuo H, Kajihara M, Tomizawa D, Watanabe T, Saito AM, Fujimoto J, Horibe K, Kodama K, Tokumasu M, Itoh H, Nakayama H, Kinoshita A, Taga T, Tawa A, Taki T, Tanaka S, Adachi S.

Blood Cancer J. 2014 Jul 11;4:e226. doi: 10.1038/bcj.2014.47.

33.

Outcome of children with relapsed acute myeloid leukemia following initial therapy under the AML99 protocol.

Nakayama H, Tabuchi K, Tawa A, Tsukimoto I, Tsuchida M, Morimoto A, Yabe H, Horibe K, Hanada R, Imaizumi M, Hayashi Y, Hamamoto K, Kobayashi R, Kudo K, Shimada A, Miyamura T, Moritake H, Tomizawa D, Taga T, Adachi S.

Int J Hematol. 2014 Aug;100(2):171-9. doi: 10.1007/s12185-014-1616-9. Epub 2014 Jun 25.

PMID:
24961644
34.

Appropriate dose reduction in induction therapy is essential for the treatment of infants with acute myeloid leukemia: a report from the Japanese Pediatric Leukemia/Lymphoma Study Group.

Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Kiyokawa N, Isoyama K, Mizutani S, Hara J, Horibe K, Nakahata T, Adachi S.

Int J Hematol. 2013 Nov;98(5):578-88. doi: 10.1007/s12185-013-1429-2. Epub 2013 Sep 26.

PMID:
24068655
35.

Mutations of the GATA2 and CEBPA genes in paediatric acute myeloid leukaemia.

Shiba N, Funato M, Ohki K, Park MJ, Mizushima Y, Adachi S, Kobayashi M, Kinoshita A, Sotomatsu M, Arakawa H, Tawa A, Horibe K, Tsukimoto I, Hayashi Y.

Br J Haematol. 2014 Jan;164(1):142-5. doi: 10.1111/bjh.12559. Epub 2013 Sep 14. No abstract available.

PMID:
24033149
36.

WT1 mutation in pediatric patients with acute myeloid leukemia: a report from the Japanese Childhood AML Cooperative Study Group.

Sano H, Shimada A, Tabuchi K, Taki T, Murata C, Park MJ, Ohki K, Sotomatsu M, Adachi S, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y.

Int J Hematol. 2013 Oct;98(4):437-45. doi: 10.1007/s12185-013-1409-6. Epub 2013 Aug 27.

PMID:
23979985
37.

A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.

Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Amano K, Takedani H, Tamashima S, Matsushita T, Tawa A, Tanaka I, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Kawakami K, Ohashi Y, Saito H.

Haemophilia. 2013 Nov;19(6):853-60. doi: 10.1111/hae.12205. Epub 2013 Jun 6.

PMID:
23738888
38.

Excess treatment reduction including anthracyclines results in higher incidence of relapse in core binding factor acute myeloid leukemia in children.

Tomizawa D, Tawa A, Watanabe T, Saito AM, Kudo K, Taga T, Iwamoto S, Shimada A, Terui K, Moritake H, Kinoshita A, Takahashi H, Nakayama H, Koh K, Kigasawa H, Kosaka Y, Miyachi H, Horibe K, Nakahata T, Adachi S.

Leukemia. 2013 Dec;27(12):2413-6. doi: 10.1038/leu.2013.153. Epub 2013 May 16. No abstract available.

PMID:
23677335
39.

NUP98-NSD1 gene fusion and its related gene expression signature are strongly associated with a poor prognosis in pediatric acute myeloid leukemia.

Shiba N, Ichikawa H, Taki T, Park MJ, Jo A, Mitani S, Kobayashi T, Shimada A, Sotomatsu M, Arakawa H, Adachi S, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y.

Genes Chromosomes Cancer. 2013 Jul;52(7):683-93. doi: 10.1002/gcc.22064. Epub 2013 Apr 30.

PMID:
23630019
40.

An Inv(16)(p13.3q24.3)-encoded CBFA2T3-GLIS2 fusion protein defines an aggressive subtype of pediatric acute megakaryoblastic leukemia.

Gruber TA, Larson Gedman A, Zhang J, Koss CS, Marada S, Ta HQ, Chen SC, Su X, Ogden SK, Dang J, Wu G, Gupta V, Andersson AK, Pounds S, Shi L, Easton J, Barbato MI, Mulder HL, Manne J, Wang J, Rusch M, Ranade S, Ganti R, Parker M, Ma J, Radtke I, Ding L, Cazzaniga G, Biondi A, Kornblau SM, Ravandi F, Kantarjian H, Nimer SD, Döhner K, Döhner H, Ley TJ, Ballerini P, Shurtleff S, Tomizawa D, Adachi S, Hayashi Y, Tawa A, Shih LY, Liang DC, Rubnitz JE, Pui CH, Mardis ER, Wilson RK, Downing JR.

Cancer Cell. 2012 Nov 13;22(5):683-97. doi: 10.1016/j.ccr.2012.10.007.

41.

Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.

Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H.

Haemophilia. 2013 Mar;19(2):330-7. doi: 10.1111/hae.12024. Epub 2012 Sep 19.

PMID:
22989180
42.

Outcome in 146 patients with paediatric acute myeloid leukaemia treated according to the AML99 protocol in the period 2003-06 from the Japan Association of Childhood Leukaemia Study.

Imamura T, Iwamoto S, Kanai R, Shimada A, Terui K, Osugi Y, Kobayashi R, Tawa A, Kosaka Y, Kato K, Hori H, Horibe K, Oda M, Adachi S; Japan Association of Childhood Leukaemia Study.

Br J Haematol. 2012 Oct;159(2):204-10. doi: 10.1111/bjh.12030. Epub 2012 Aug 28.

PMID:
22924344
43.

High WT1 mRNA expression after induction chemotherapy and FLT3-ITD have prognostic impact in pediatric acute myeloid leukemia: a study of the Japanese Childhood AML Cooperative Study Group.

Shimada A, Taki T, Koga D, Tabuchi K, Tawa A, Hanada R, Tsuchida M, Horibe K, Tsukimoto I, Adachi S, Kojima S, Hayashi Y.

Int J Hematol. 2012 Oct;96(4):469-76. doi: 10.1007/s12185-012-1163-1. Epub 2012 Aug 23.

PMID:
22915059
44.

Clinical characteristics and outcome of refractory/relapsed myeloid leukemia in children with Down syndrome.

Taga T, Saito AM, Kudo K, Tomizawa D, Terui K, Moritake H, Kinoshita A, Iwamoto S, Nakayama H, Takahashi H, Tawa A, Shimada A, Taki T, Kigasawa H, Koh K, Adachi S.

Blood. 2012 Aug 30;120(9):1810-5. doi: 10.1182/blood-2012-03-414755. Epub 2012 Jul 9.

45.

RAS mutations are frequent in FAB type M4 and M5 of acute myeloid leukemia, and related to late relapse: a study of the Japanese Childhood AML Cooperative Study Group.

Sano H, Shimada A, Taki T, Murata C, Park MJ, Sotomatsu M, Tabuchi K, Tawa A, Kobayashi R, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Hayashi Y.

Int J Hematol. 2012 May;95(5):509-15. doi: 10.1007/s12185-012-1033-x. Epub 2012 Mar 10.

PMID:
22407852
46.

DNMT3A mutations are rare in childhood acute myeloid leukaemia, myelodysplastic syndromes and juvenile myelomonocytic leukaemia.

Shiba N, Taki T, Park MJ, Shimada A, Sotomatsu M, Adachi S, Tawa A, Horibe K, Tsuchida M, Hanada R, Tsukimoto I, Arakawa H, Hayashi Y.

Br J Haematol. 2012 Feb;156(3):413-4. doi: 10.1111/j.1365-2141.2011.08879.x. Epub 2011 Oct 8. No abstract available.

PMID:
21981547
47.

Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.

Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H.

Haemophilia. 2012 Jan;18(1):94-101. doi: 10.1111/j.1365-2516.2011.02548.x. Epub 2011 Apr 28.

PMID:
21535327
48.

Prospective study of a therapeutic regimen with all-trans retinoic acid and anthracyclines in combination of cytarabine in children with acute promyelocytic leukaemia: the Japanese childhood acute myeloid leukaemia cooperative study.

Imaizumi M, Tawa A, Hanada R, Tsuchida M, Tabuchi K, Kigasawa H, Kobayashi R, Morimoto A, Nakayama H, Hamamoto K, Kudo K, Yabe H, Horibe K, Tsuchiya S, Tsukimoto I.

Br J Haematol. 2011 Jan;152(1):89-98. doi: 10.1111/j.1365-2141.2010.08332.x.

PMID:
20735397
49.

Prognostic significance of the BAALC isoform pattern and CEBPA mutations in pediatric acute myeloid leukemia with normal karyotype: a study by the Japanese Childhood AML Cooperative Study Group.

Mizushima Y, Taki T, Shimada A, Yui Y, Hiraumi Y, Matsubara H, Watanabe M, Watanabe K, Kamitsuji Y, Hayashi Y, Tsukimoto I, Kobayashi R, Horibe K, Tawa A, Nakahata T, Adachi S.

Int J Hematol. 2010 Jun;91(5):831-7. doi: 10.1007/s12185-010-0585-x. Epub 2010 May 22.

PMID:
20495894
50.

Mosaic Down syndrome-associated acute myeloid leukemia does not require high-dose cytarabine treatment for induction and consolidation therapy.

Kudo K, Hama A, Kojima S, Ishii R, Morimoto A, Bessho F, Sunami S, Kobayashi N, Kinoshita A, Okimoto Y, Tawa A, Tsukimoto I.

Int J Hematol. 2010 May;91(4):630-5. doi: 10.1007/s12185-010-0549-1. Epub 2010 Mar 18.

PMID:
20237876

Supplemental Content

Support Center